Eris Lifesciences Ltd

The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the acquisition of balance 30% of the total share capital of Swiss Parenterals, a subsidiary of the Company. Further, the board has approved the issuance of up to 23,06,372 equity shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals. Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 24 November 2025.Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 31.23% to Rs 120.19 crore in the quarter ended September 2025 as against Rs 91.59 crore during the previous quarter ended September 2024. Sales rose 6.93% to Rs 790.15 crore in the quarter ended September 2025 as against Rs 738.95 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales790.15738.95 7 OPM %36.4835.80 - PBDT241.75209.59 15 PBT172.67129.11 34 NP120.1991.59 31 Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live

Eris Lifesciences has allotted 6,761 equity shares under ESOP on 30 August 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,62,06,793/- (13,62,06,793 equity shares of Re. 1/- each) to Rs. 13,62,13,554/- (13,62,13,554 equity shares of Re. 1/- each).Powered by Capital Market - Live

Eris Lifesciences announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from Anvisa, Brazil's national health regulatory agency. This facility is part of subsidiary Swiss Parenterals that was acquired by Eris in 2024. The approval follows a successful inspection conducted by the regulatory agency in April 2025 of both the injectable facilities of Swiss Parenterals, and the company expects to receive approval for the second facility soon. Both facilities are already EU GMP and PIC/s approved and supply a range of products to several Latin American markets including Mexico, Chile, Argentina and Peru. A company spokesperson said that the Anvisa approval would enable the company to launch its products in Brazil and achieve comprehensive coverage of the Latin American pharma market. Commenting on the development, Amit Bakshi, CMD of Eris said, 'We take this approval as yet another endorsement of our operating and quality standards in life-saving dosage forms like injectables. This approval takes us a step forward in our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology. We made major investments to initiate this transformation last year and we are glad to note that we have made significant progress in creating value from these investments with many more exciting developments expected in the quarters to come.'Powered by Capital Market - Live

Eris Lifesciences announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil's national health regulatory agency. This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the Company's manufacturing facilities. The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.Powered by Capital Market - Live

This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter the Brazilian market, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the company's manufacturing facilities. The said manufacturing facility was also successfully inspected by various other regulatory agencies earlier this year. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company's consolidated net profit rose 41.63% to Rs 117.99 crore on a 7.82% increase in revenue to Rs 771.56 crore in Q1 FY26 as compared with Q1 FY25. The scrip advanced 0.17% to currently trade at Rs 1771.85 on the BSE. Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 41.63% to Rs 117.99 crore in the quarter ended June 2025 as against Rs 83.31 crore during the previous quarter ended June 2024. Sales rose 7.82% to Rs 771.56 crore in the quarter ended June 2025 as against Rs 715.59 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales771.56715.59 8 OPM %35.8634.93 - PBDT231.61191.26 21 PBT161.10115.52 39 NP117.9983.31 42 Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 5 August 2025.Powered by Capital Market - Live